On Wednesday 16 July the Government published the Life Sciences Sector Plan, forming a vital part of the industrial strategy.
Responding, Prof Siddharthan Chandran, Director of the UK Dementia Research Institute said:
"The Government's Life Science Sector Plan correctly identifies that our increasingly complex, ageing population presents the UK's most pressing health and economic challenge. As the national institute dedicated to transforming through research healthy brain ageing for all, the UK Dementia Research Institute is uniquely positioned to deliver meaningful solutions. To support the ambitions of this plan, we will work in partnership with government, industry and the NHS to position the UK as a global hub for investment and innovation, putting UK in the box seat driving transformational change in healthy brain ageing.
Since its inception in 2017, investment in UK Dementia Research Institute’s discovery science has already resulted in the creation of multiple successful spinouts including AviadoBio and Acionna Therapeutics: UK-based companies developing new therapies for patients living with neurodegenerative conditions.
Today's announcements to streamline clinical trial setup and harness the UK’s exceptional health data capabilities will be transformative for researchers across the entire pipeline – from human-centred discovery research through to real-world translation that delivers meaningful impact for people living with or at risk of neurodegenerative conditions. We are committed to working with the Government to leverage the best of UK life science, building toward a future where we can predict, prevent and personalise diagnosis, treatment and care for all."